Narinder Janghra

754 total citations
14 papers, 461 citations indexed

About

Narinder Janghra is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Narinder Janghra has authored 14 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Narinder Janghra's work include CAR-T cell therapy research (5 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer therapeutics and mechanisms (3 papers). Narinder Janghra is often cited by papers focused on CAR-T cell therapy research (5 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer therapeutics and mechanisms (3 papers). Narinder Janghra collaborates with scholars based in United Kingdom, Netherlands and India. Narinder Janghra's co-authors include Jennifer E. Morgan, Francesco Muntoni, Haiyan Zhou, Patrick H. van Berkel, Francesca Zammarchi, Philip W. Howard, John A. Hartley, Teresa Marafioti, Peter Tyrer and David G. Williams and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Narinder Janghra

13 papers receiving 445 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Narinder Janghra United Kingdom 7 257 192 160 95 75 14 461
Wendy Zhong United States 6 139 0.5× 158 0.8× 28 0.2× 82 0.9× 15 0.2× 9 318
Simona Martin Germany 8 72 0.3× 130 0.7× 92 0.6× 25 0.3× 107 1.4× 12 327
Shaio Woo United States 4 142 0.6× 60 0.3× 157 1.0× 62 0.7× 44 0.6× 4 364
Suzanne E. Berry United States 12 271 1.1× 56 0.3× 65 0.4× 16 0.2× 72 1.0× 14 360
Chia‐Ing Jan Taiwan 14 305 1.2× 142 0.7× 46 0.3× 68 0.7× 14 0.2× 21 633
Rouzanna Istvánffy Germany 12 150 0.6× 155 0.8× 57 0.4× 34 0.4× 25 0.3× 31 408
Anne‐Sophie Wozny France 14 233 0.9× 189 1.0× 19 0.1× 114 1.2× 21 0.3× 29 557
Maritza E. Mayorga United States 12 219 0.9× 34 0.2× 60 0.4× 22 0.2× 28 0.4× 14 432
Philip Vlummens Belgium 13 323 1.3× 124 0.6× 39 0.2× 25 0.3× 33 0.4× 33 503

Countries citing papers authored by Narinder Janghra

Since Specialization
Citations

This map shows the geographic impact of Narinder Janghra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Narinder Janghra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Narinder Janghra more than expected).

Fields of papers citing papers by Narinder Janghra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Narinder Janghra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Narinder Janghra. The network helps show where Narinder Janghra may publish in the future.

Co-authorship network of co-authors of Narinder Janghra

This figure shows the co-authorship network connecting the top 25 collaborators of Narinder Janghra. A scholar is included among the top collaborators of Narinder Janghra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Narinder Janghra. Narinder Janghra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Cucchi, Danilo, et al.. (2025). Abstract 1580: HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-expressed in both solid and hematological cancers. Cancer Research. 85(8_Supplement_1). 1580–1580. 1 indexed citations
2.
Zammarchi, Francesca, Karin Havenith, Narinder Janghra, et al.. (2024). ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies. Molecular Cancer Therapeutics. 23(4). 520–531. 6 indexed citations
3.
Horsley, Elizabeth, et al.. (2024). Abstract 3122: Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6. Cancer Research. 84(6_Supplement). 3122–3122. 2 indexed citations
4.
Horsley, Elizabeth, et al.. (2024). Abstract 5085: Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b. Cancer Research. 84(6_Supplement). 5085–5085. 1 indexed citations
5.
Zammarchi, Francesca, Simon Corbett, Lauren Adams, et al.. (2018). ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 131(10). 1094–1105. 118 indexed citations
6.
7.
Zammarchi, Francesca, Narinder Janghra, Simon Corbett, et al.. (2017). Abstract 52: Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors. Cancer Research. 77(13_Supplement). 52–52. 4 indexed citations
8.
Flynn, Michael, Francesca Zammarchi, Peter Tyrer, et al.. (2016). ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Molecular Cancer Therapeutics. 15(11). 2709–2721. 85 indexed citations
9.
Janghra, Narinder, Jennifer E. Morgan, Caroline A. Sewry, et al.. (2016). Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies. PLoS ONE. 11(3). e0150818–e0150818. 34 indexed citations
10.
11.
Flynn, Michael, Patrick H. van Berkel, Francesca Zammarchi, et al.. (2015). Mechanistic and Pharmacodynamic Studies of Adct-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Blood. 126(23). 1559–1559. 6 indexed citations
12.
Zhou, Haiyan, Narinder Janghra, Chalermchai Mitrpant, et al.. (2013). A Novel Morpholino Oligomer Targeting ISS-N1 Improves Rescue of Severe Spinal Muscular Atrophy Transgenic Mice. Human Gene Therapy. 24(3). 331–342. 100 indexed citations
13.
Anthony, Karen, Virginia Arechavala‐Gomeza, Valeria Ricotti, et al.. (2013). Biochemical Characterization of Patients With In-Frame or Out-of-FrameDMDDeletions Pertinent to Exon 44 or 45 Skipping. JAMA Neurology. 71(1). 32–32. 58 indexed citations
14.
Tucker, Elizabeth R., Andrea Buda, Narinder Janghra, et al.. (2003). Abnormalities of the cadherin–catenin complex in chemically-induced colo-rectal carcinogenesis. Proceedings of The Nutrition Society. 62(2). 571–571. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wendy Zhong Breakdown of academic impact, for papers by Simona Martin Breakdown of academic impact, for papers by Shaio Woo Breakdown of academic impact, for papers by Suzanne E. Berry Breakdown of academic impact, for papers by Chia‐Ing Jan Breakdown of academic impact, for papers by Rouzanna Istvánffy Breakdown of academic impact, for papers by Anne‐Sophie Wozny Breakdown of academic impact, for papers by Maritza E. Mayorga Breakdown of academic impact, for papers by Philip Vlummens
Rankless by CCL
2026